Px HealthCare Unveils First-of-its-Kind, Real World Evidence Study Using OWise Breast Cancer Patient Support App
LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
- LONDON, Dec. 7, 2023 /PRNewswire/ -- Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium (SABCS).
- The study, which is part of a collaboration between Px and AstraZeneca UK, is a nationwide RWE initiative enabling any breast cancer patient in the UK to take part in the study when prescribed with trastuzumab deruxtecan (TDX-d, Enhertu) or olaparib (Lynparza) using the OWise app.
- Founder & CEO of Px, Dr. Anne Bruinvels, said, "The RELATE-2 study is an exciting novel way to conduct patient-centred Real World Evidence research.
- With the freely available OWise breast cancer app patients prescribed with TDX-d or olaparib can find personalized support.